WO2010013846A1 - 新規悪性中皮腫治療剤及び免疫賦活化剤 - Google Patents
新規悪性中皮腫治療剤及び免疫賦活化剤 Download PDFInfo
- Publication number
- WO2010013846A1 WO2010013846A1 PCT/JP2009/063907 JP2009063907W WO2010013846A1 WO 2010013846 A1 WO2010013846 A1 WO 2010013846A1 JP 2009063907 W JP2009063907 W JP 2009063907W WO 2010013846 A1 WO2010013846 A1 WO 2010013846A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- base sequence
- kuta
- cell
- dkk
- complementary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Definitions
- the present invention relates to malignant agents and agents.
- the gastrointestinal and visceral organs and the heart are encased in membranes such as the pleura and membrane, respectively, and cover the surface of these membranes. When this skin occurred. Depending on the position, there are pleura, peritoneum and tumor.
- oday therapy which is a combination of conventional surgery, chemotherapy, and radiation therapy, is the mainstay, it still has 5 lives and 0, and it is a malignant refractory period.
- E Dkk 3 was found at Okayama University as a gene whose expression decreases with the occurrence of human normal cells, and it is clear that it is homologous to the milk of the kk d ckkop) gene involved in the formation of enopus. It is a strange thing (See and below). In studies with human prostate cancer, it was found that infection with E Dkk 3 virus (dE) produced some kind of stoma and activated c un NK nase (JNK) to induce pothos. (See 2).
- the purpose is to provide a method for malignant treatment using E kk 3 and to include E kk 3. Furthermore, the purpose is to provide a method using E kk 3 and a preparation containing E kk 3.
- the viable vector pleural transmission rate is always excellent, and the same L 7 life is redundant in normal cells. It is thought to be centered on the cell.
- E Dkk 3 activates and activates the N cell by enhancing the L 7 viability of normal cells.
- N or consisting of the base sequence represented by (a), including the following E kk 3DN or Kuta containing the N as an active ingredient
- N is a base sequence that is complementary to the base sequence shown in (b), and N is a host that has a host property and a cell L 7 property.
- N consisting of the base sequence represented by (a) or
- N consisting of a base sequence that is complementary to the base sequence shown in (b), which is N in a stringent condition and has a host and a cell L7 property.
- E kk 3DN or Kuta containing the DN is administered to the chest cavity.
- N consisting of the base sequence represented by (a) or
- N is composed of a base sequence complementary to the base sequence shown in (b), and N is a target that possesses a potency and a cell L7 property.
- 6 Kuta is a vector of 5's.
- E kk 3 DN or Kuta containing the DN is administered into the thoracic cavity. Ninety-eight possible to induce a pot to the cell, and the cell is broken.
- DN consisting of the base sequence represented by (a) or
- DN consisting of the base sequence represented by (a) or
- (b) DN that is a base sequence that is complementary to the base sequence shown in (b) and that has a site condition, and that contains a host and a L 7 property of a cell.
- N In the base sequence complementary to the base sequence shown in (b) N, which is a complex condition, and has a potency and a cell L7 property.
- Fig. 3 is a diagram showing 2 H cell pot conduction by E kk 3.
- Figure 2 shows the progression of JNK pcn and activation cusp 3 at 2 H by E kk 3.
- Fig. 3 is a diagram showing JKK Lee's control of E kk 3's potential at 2H.
- Figure 4 shows the current control of d at 2 H by E Dkk 3.
- Fig. 5 is a diagram showing a small amount of potential induced by E Dkk 3 at 2 H due to d-regulated expression.
- Fig. 6 shows the current regulation of PJNK pcun and activated cusp 3 driven by E Dkk 3 at 2 H by d-regulation expression.
- Fig. 7 is a diagram showing the post-conduction of H28 cells and H0202 cells by E kk 3.
- Fig. 8 is a diagram showing a small amount of postpotentiation induced by E kk 3 in H28 cells and H2052 due to d-regulated expression.
- ga is a diagram showing the results of E kk 3 in a Nudus transplanted with HL c vesicles.
- gb is a diagram showing an image showing the result of E kk 3 in a Nudus transplanted with 2 H Luc cells.
- FIG. 4 is a view showing the state of E C Dkk 3 in a normal membrane.
- FIG. 4 is a diagram showing the use of E kk 3 in normal cells.
- FIG. 2 is a diagram showing EDkk 3 for L 7 in a normal cell (cytokine eye).
- Fig. 3 is a diagram showing EDkk 3 for L 7 in normal cells (Northern).
- FIG. 4 is a diagram showing L 7 of E kk 3.
- FIG. 5 is a diagram showing the offspring biological mechanism caused by E kk 3. Good for carrying out Ming
- the edk 3DN or the K containing this N is effective.
- the base sequence of RE kk 3 DN is shown in Sequence. In addition, it is represented by an anosequence 2 of the E kk 3 protein that is recorded by E Dkk 3 DN.
- the E kk 3 DN contained in the photo has the amino acid sequence represented by sequence 2 and the amino acid sequence represented by sequence 2, and has the potential for And it is a protein with intercellular 7 (L7) properties.
- L7 protein with intercellular 7
- Ano BL Bas cLoca gnmen ea ch Too a he Na ona eneo Bo canoganoa National Center for Biological Sciences
- an anoic acid substituted, deleted and / or added E.g., using auto or constant ram
- at least 85, preferably 9 Up Further preferred are those having the identity of 95, particularly preferred of 97.
- E Dkk 3DN can be obtained by chemical synthesis based on the information on sequence or sequence 2. It can also be obtained as an E kk 3 tank by genetic engineering techniques. Furthermore, it is also possible to obtain it according to 00 038523.
- the E Dkk 3DN included in the light is a N sequence that has a base sequence that is complementary to the base sequence represented by the sequence N, the base sequence represented by the sequence, BLT (Bas cLoca gn en Sea ch Too a he Na ona en eo Bo og ca no ma on (for example, using the national laboratory of biological science)
- BLT Base cLoca gn en Sea ch Too a he Na ona en eo Bo og ca no ma on (for example, using the national laboratory of biological science)
- Cells such as N that contain a protein consisting of an anodic acid substituted, deleted, or added amino acid This is a tag that has the potential to antagonize the cell and the italic 7 (L 7) property.
- strict conditions are, for example, 0 ⁇ DS.
- E Dkk 3DN contained in Ming is N, which is the tag that represents the property shown in Sequence 2.
- RE kk 3DN can be a human, a human, etc. based on the sequence information. It is also possible to obtain it according to 001 038523.
- Kuta including E kk 3 N is also included.
- the test E kk 3 protein is expressed by Can produce results for tumors.
- the target gene in gene therapy can be achieved by the body law of the gene (N).
- N body law of the gene
- a typical method for transferring genes is to use a vector such as Adewis, Adewis (), and Twis. Introduced genes targeted for N or N virus such as Twice, Swiss, Wax, Pox, Poio, Bis, Sedai, 40 Disease Infectious Disease (H) However, it is possible to introduce a cell gene by infecting cells with a tissue virus.
- Adequate instructors are preferred when using the genes related to light for gene therapy using ice.
- Ade-Wysuta it is possible to transfer into the cells of the type (), efficiently transfer into the cells of (2), and (3) the size can be reduced by the heart. (4) It is suitable for the transfer of nV vo cell contacts.
- E2 or E4 area was lacking as a gene therapy treatment in addition to E E3 area, such as Ey3, which was a substitute for the E E3 area (yake ea Poc Na cad c U 93 320 996)
- the second-generation Wistar (Lebe eaJo 0 944 996 z guch H Kay, Hene he, 10 2013 999), the Adewis genome almost completely absent (U LE), the third-generation Wisbe (en ae de ⁇ ea ⁇ J ⁇ o ⁇ 73 9303 999) has been developed, but there is no particular limitation on the introduction of the genes related to the light, and it can be used with any of the above-mentioned ones.
- an id tractor with built-in ability added to ecchaea Poc Naca Sc U 96 2615 999
- Wisvector that has the ability to be incorporated into chromosomes by using the Laspo gene, it can be applied to long-term gene expression. It is. It is also possible to add tissue isomerism to the Adewi sector by inserting a column indicating organizational transition in the Adewi Sui H group (zug ch H Hayakawa TN pon nsho 7 544 000)
- the target gene can be introduced into a cell or tissue using a kuta in which a gene kuta such as a plasta is incorporated.
- cell genes can be introduced by the method of DN using a liposome, um, E E xystra or micro glass tube.
- a gene by an encapsulated liposome ne na poso
- a gene by an electrostatic liposome e ecoos ac ype posoe
- HJ population e ecoos ac ype posoe
- HJE population e ecoos ac ype posoe
- Kuta can be taken into cells.
- an expression vector used in this case an expression vector that can express a target gene in a living body can be used.
- p ene 08 193 200 (1991)
- p pc N 3, 1, p eo Ibigue, Stratagene
- p eo Ibigue, Stratagene
- the ect containing E kk 3DN may contain a transferor for transcribing the gene, a guna, a gene for introducing and identifying the cell into which the gene was introduced.
- a motor can be used.
- nVvo In order to enter the Kuta containing Mt. E kk 3DN, nVvo, which directly introduces gene therapy, removes certain cells from humans, and 0 Use ex V vo to introduce the gene therapy cell outside and return the cell to the body (Sci, 1994, No. 24, 45, 36 () 23 48 (1994), 2 (15) 1994 ) Gene Therapy Association, Gene Therapy Dock, Nu Ti, 999)
- malignant including pleura, peritoneum.
- malignant preference is preferred.
- the medicine contains an agent containing the above-mentioned E Dkk 3DN or the N-containing Kuta.
- L7 quinone can be administered in the form of clear, L7 quinone and can be administered by oral administration with drugs, capsules, powders, pills, or injections, infusions, suppositories, sps, eye drops, transdermal, drugs, etc. Oral administration can be mentioned.
- the effect can be exerted by administration.
- L7 bases and dilutions commonly used in the pharmaceutical field.
- steanium is used.
- physiological saline, grapes and other fluids containing supplements are used, and appropriate dissolution, such as apples and pigs, is used.
- Hea and malignant 2 H, 28 cells and 2052 cells were used. These were obtained from T (me canType eueoeco). , (FBS, 2 gta, 100 m, 100 use P 640 (B) with g m stop-in added 37.
- the Wisctor (d E) containing E kk 3 DN was prepared by the following method.
- the full length E kk 3 CN was introduced into x, and was transferred to the virus vector by TP (Taka a Bo) (ba za F ea ance es 2000 65 9617 9622). Lac) was taken as a control.
- the 2 H transactant (2 H Luc) that stably expresses the phrase gene is expressed as Kash aka a e cu a on 003 07 1078 8
- nne (apotos) was performed by the following method. That is, in order to adjust cell conduction at nVo, the cells were cultured 24 times in 6-up. The cells were treated in serum-free soil with dLac d E upc yOn econon) and then replaced with fresh ground. 48 excitement, n Su Ce ea h De ec on Foesce nk (oche Dagnos cs was used to evaluate TUNEL (e na deoxynuc eo dy ansease ed a edU P abe n). The total number of cells in 100 cells (P) was analyzed, and the cells in which were observed were counted in 3 to 5 fields under a microscope.
- TUNEL was performed using nSueDeecoKFuocece (oche) to detect cells in which cells were observed with nVvo. That is, the weaving was cut, put into a T compound and rapidly set in the element. The (0) sup was fixed with methano at 30 room temperature, PB containing 0.1 T on 00 was allowed to stain, and stained with TUNEL.
- Figure 2 shows the results of the cell bust analysis used. As shown in Fig. 2, the actual state of Pc acve Caspase 3 was increased in d E feeling. In other words, it was proved that the d E infection causes a postpot through JNK sex.
- JNK nh bo was added to the post-up.
- the results are shown in FIG. JNK nh b o significantly suppressed d E pot.
- JNK nh b o significantly suppressed d E pot.
- the following experiment was conducted in order to regulate the development of proteins caused by dE infection at nVo.
- the cells are fed 24 times in 6-up, and the cells are serum-free with d Lac d E at 20 0 (mpc yOn ec on). After doing 2 inside, it was replaced with fresh ground. Forty-eight inkbaths and tanks were collected and rusted.
- Figure 4 shows the results of the Ustat analysis of nh bo O de en a on d). As shown in Fig. 4, after 48 hours of d sensation, the actual state of d decreased at 2 H.
- Fig. 6 shows the results of ustab analysis in the cells used in a e a (2 H without any treatment) 5.
- the increase in dE pJNK pc and cveCaspase 3 was suppressed by d-regulated expression.
- JNK sexualization which is the main mechanism of the d RE point, was harmed by d expression.
- An orthotopic malignant deus was prepared by giving 2.06 HLc in 00 LPBS to 8 B LB nudus (obtained from L).
- ga shows the quantification (ho on sec) of 2 H L () by. Compared to the previous day (Day 0), d E significantly decreased in ay 0.
- gb represents an image corresponding to ga.
- the d Lac sensation mouse used in (4) was dissected 7 days after infection, and the appearance of the gene Lac in the inner and membranes was analyzed with the Lac color separated into normal tissues. Lac color below.
- PB H8 0 home dehydr 37 2 7m, 0 ⁇ 2 gluta dehydrate 25 0 8 2 g 0 2 5 E 200 2 5m
- ac PB 50m 5 fan cathode 0 2 5m , 5m 2a 2 0m 0 0 0 o u Deoxycho ae 0 0 0 5 0 0 2 NP40 0 0 0 gm ga 50 g
- the appearance of 2 ink Lac was analyzed at room temperature.
- Oa shows the results of gene analysis by Lac color in the d Lac group. As shown in Oa, a gene was introduced into 50 cells of the cell, but no gene was found in the remaining cells. Nonetheless, there are some negative effects, so d E It was thought that there was a use.
- D E was performed using human cells.
- U 24 was used as a human. These were established by (Ba Le an J ance 993 53 45 456)
- the cells were treated with dE at 20 0 and infected with dE.
- Figure 6 shows the color results when dE is infected into normal cells. It was confirmed that the expressed E was in the cells ().
- the site of the upper site when d normal cells were infected with E was determined using site sites.
- the site Kai Ai used ayB o Huan y ok ne n body ay 6 (ayB o ech No c oss).
- Figure 2 shows the results. As shown in Fig. 2, an increase in L 7 was confirmed.
- Fig. 3 shows the results of the nozat analysis on the d E normal line 3, ex E shows the binato E quality. As shown in Fig. 3, it was confirmed that the d 7 E sensitivity line was based on the current state of L 7 N.
- L 7 life is derived from infection of normal cells by dE.
- L 7 activates N Na ua K vesicles
- Figure 5 shows the offspring biological mechanism caused by d E giving. As shown in Fig. 5, there are two paths: d-regulation and p38 sexualization. Causing the pot to the cell, the latter
- the amount of E kk 3 N applied to the adenoviral vector (dE) to the local malignant deus () is reduced in quantity and the survival is improved.
- the amount was reduced significantly by giving d RE C (), and good survival was observed.
- no obvious effect was observed.
- the JK point is due to nh b on Ode a on (d), which is closely related to cell growth.
- dE can exert a wide variety of results.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010522773A JP5551593B2 (ja) | 2008-07-30 | 2009-07-30 | 新規悪性中皮腫治療剤及び免疫賦活化剤 |
EP09803076.0A EP2327779B1 (en) | 2008-07-30 | 2009-07-30 | New therapeutic agent for malignant mesothelioma and immunostimulant |
US13/056,443 US8658612B2 (en) | 2008-07-30 | 2009-07-30 | Therapeutic agent for malignant mesothelioma and immunostimulant |
CN2009801360548A CN102159709B (zh) | 2008-07-30 | 2009-07-30 | 用于恶性间皮瘤的新型治疗剂和免疫刺激剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008196857 | 2008-07-30 | ||
JP2008-196857 | 2008-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010013846A1 true WO2010013846A1 (ja) | 2010-02-04 |
Family
ID=41610533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/063907 WO2010013846A1 (ja) | 2008-07-30 | 2009-07-30 | 新規悪性中皮腫治療剤及び免疫賦活化剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8658612B2 (ja) |
EP (1) | EP2327779B1 (ja) |
JP (2) | JP5551593B2 (ja) |
CN (1) | CN102159709B (ja) |
WO (1) | WO2010013846A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083686B (zh) * | 2013-02-18 | 2014-09-10 | 上海交通大学医学院附属仁济医院 | Dkk4基因及其编码蛋白在制备药物中的应用 |
EP3041494A4 (en) | 2013-09-05 | 2017-10-18 | Sanford-Burnham Medical Research Institute | Modulation of gamma delta t cells |
RU2767997C2 (ru) * | 2016-01-08 | 2022-03-22 | Момотаро-Джин Инк. | КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ ГЕНА REIC/Dkk-3 И ИНГИБИТОРА КОНТРОЛЬНОЙ ТОЧКИ ИММУННОГО ОТВЕТА |
JP7386553B2 (ja) * | 2018-11-01 | 2023-11-27 | 桃太郎源株式会社 | Ad-REIC/Dkk-3とチェックポイント阻害剤とを用いた胸部がんの治療のための併用療法 |
JPWO2022091809A1 (ja) | 2020-10-28 | 2022-05-05 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008523A1 (fr) | 2001-07-18 | 2003-01-30 | Nok Kluber Co., Ltd. | Composition d'huile lubrifiante |
WO2006098074A1 (ja) * | 2005-03-15 | 2006-09-21 | Hiromi Kumon | 前立腺癌細胞のアポトーシス誘発剤 |
JP2008196857A (ja) | 2007-02-08 | 2008-08-28 | Hitachi Ltd | カーナビゲーション装置 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770282B1 (en) * | 1998-10-23 | 2004-08-03 | Heska Corporation | Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
WO2001038528A1 (fr) | 1999-11-19 | 2001-05-31 | Hisamitsu Pharmaceutical Co., Inc. | Proteine inhibitrice de la proliferation cellulaire, polynucleotide, polynucleotide antisens de ce polynucleotide, inhibiteurs de proliferation cellulaire, diagnostics de cancers, remedes anticancereux et composition pour therapie genique les utilisant |
CN1296967A (zh) | 1999-11-23 | 2001-05-30 | 上海博容基因开发有限公司 | 一种新的多肽——人耳聋相关基因14和编码这种多肽的多核苷酸 |
TWI350175B (en) * | 2003-10-17 | 2011-10-11 | Chugai Pharmaceutical Co Ltd | Mesothelioma therapeutic agent |
EP2508606B1 (en) | 2006-10-24 | 2017-09-13 | Momotaro-Gene Inc. | Partial fragment of REIC/Dkk-3 gene and therapeutic agent for cancer containing the same |
-
2009
- 2009-07-30 CN CN2009801360548A patent/CN102159709B/zh active Active
- 2009-07-30 US US13/056,443 patent/US8658612B2/en active Active
- 2009-07-30 EP EP09803076.0A patent/EP2327779B1/en active Active
- 2009-07-30 JP JP2010522773A patent/JP5551593B2/ja active Active
- 2009-07-30 WO PCT/JP2009/063907 patent/WO2010013846A1/ja active Application Filing
-
2014
- 2014-05-22 JP JP2014106448A patent/JP2014208650A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008523A1 (fr) | 2001-07-18 | 2003-01-30 | Nok Kluber Co., Ltd. | Composition d'huile lubrifiante |
WO2006098074A1 (ja) * | 2005-03-15 | 2006-09-21 | Hiromi Kumon | 前立腺癌細胞のアポトーシス誘発剤 |
JP2008196857A (ja) | 2007-02-08 | 2008-08-28 | Hitachi Ltd | カーナビゲーション装置 |
Non-Patent Citations (23)
Title |
---|
"Experimental Medicine (additional volume)", 1996, YODOSHA CO., LTD., article "Basic Techniques for Gene Therapy" |
"Experimental Medicine (additional volume)", 1997, YODOSHA CO., LTD., article "Experimental Methods for Gene Transfection & Expression Analysis" |
"Handbook for Gene Therapy Research and Development", 1999, NTS INC. |
ABARZUA ET AL., CANCER RES., vol. 65, 2005, pages 1617 - 22 |
ABARZUA F ET AL., CANCER RES, vol. 65, 2005, pages 9617 - 9622 |
ABARZUA, FERNANDO ET AL.: "Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-Kinase.", CANCER RESEARCH, vol. 65, no. 21, 2005, pages 9617 - 9622, XP002998788 * |
ABARZUA, FERNANDO ET AL.: "Heat shock proteins play a crucial role in tumor-specific apoptosis by REIC/Dkk-3.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 20, 2007, pages 37 - 43, XP008144322 * |
BAI L ET AL., INT J CANCER, vol. 53, 1993, pages 451 - 456 |
EDAMURA, K. ET AL.: "Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model.", CANCER GENE THERAPY, vol. 14, no. 9, 2007, pages 765 - 772, XP008133671 * |
EXPERIMENTAL MEDICINE, vol. 12, no. 15, 1994 |
GENE, vol. 108, 1991, pages 193 - 200 |
KASHIWAKURA Y. ET AL., CIRCULATION, vol. 107, pages 1078 - 81 |
LIEBER, A. ET AL., J. VIROL., vol. 70, 1996, pages 8944 |
MIYAKE, S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 93, 1996, pages 1320 |
MIZUGUCHI, H., HAYAKAWA, T., NIPPON RINSHO, vol. 7, 2000, pages 1544 |
MIZUGUCHI, H., KAY, M. A., HUM. GENE THER., vol. 10, 1999, pages 2013 |
NIKKEI, SCIENCE, vol. 4, 1994, pages 20 - 45 |
RECCHIA, A. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2615 |
See also references of EP2327779A4 |
STEINWAERDER, D. S. ET AL., J. VIROL., vol. 73, 1999, pages 9303 |
TANIMOTO, RYUTA ET AL.: "REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 19, 2007, pages 363 - 368, XP008133672 * |
THE PHARMACEUTICALS MONTHLY, vol. 36, no. 1, 1994, pages 23 - 48 |
TSUJI, T. ET AL., BIOCHEMBIOPHYS RES COMMUN, vol. 268, 2000, pages 20 - 4 |
Also Published As
Publication number | Publication date |
---|---|
CN102159709B (zh) | 2013-07-24 |
US20110189237A1 (en) | 2011-08-04 |
EP2327779A1 (en) | 2011-06-01 |
EP2327779A4 (en) | 2012-03-07 |
US8658612B2 (en) | 2014-02-25 |
JPWO2010013846A1 (ja) | 2012-01-12 |
JP5551593B2 (ja) | 2014-07-16 |
JP2014208650A (ja) | 2014-11-06 |
EP2327779B1 (en) | 2017-09-20 |
CN102159709A (zh) | 2011-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rahman et al. | Oncolytic virotherapy with myxoma virus | |
Bai et al. | Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy | |
Lassiter et al. | Nano-pulse stimulation ablates orthotopic rat hepatocellular carcinoma and induces innate and adaptive memory immune mechanisms that prevent recurrence | |
CN103212071B (zh) | 干细胞融合癌发生模型 | |
Chulpanova et al. | Recombinant viruses for cancer therapy | |
WO2010013846A1 (ja) | 新規悪性中皮腫治療剤及び免疫賦活化剤 | |
Gupta et al. | Recent advances in cancer vaccines: challenges, achievements, and futuristic prospects | |
Cadena et al. | Radiation and anti-cancer vaccines: a winning combination | |
Kciuk et al. | Recent advances in molecular mechanisms of cancer immunotherapy | |
Vasileva et al. | Double recombinant vaccinia virus: A candidate drug against human glioblastoma | |
Pastorakova et al. | Suicide gene therapy mediated with exosomes produced by mesenchymal stem/stromal cells stably transduced with HSV thymidine kinase | |
Adkins et al. | High hydrostatic pressure in cancer immunotherapy and biomedicine | |
Hofman et al. | The multifaceted role of macrophages in oncolytic virotherapy | |
Kozak et al. | Replication and oncolytic activity of an avian orthoreovirus in human hepatocellular carcinoma cells | |
Hao et al. | Photodynamic therapy in combination with the hepatitis B core virus-like particles (HBc VLPs) to prime anticancer immunity for colorectal cancer treatment | |
Luz et al. | Clinical applications and immunological aspects of electroporation-based therapies | |
CN101642577A (zh) | 人类ing4基因作为放疗增敏剂的应用 | |
Hilchie et al. | MDA-MB-231 breast cancer cells resistant to pleurocidin-family lytic peptides are chemosensitive and exhibit reduced tumor-forming capacity | |
Bulvik et al. | Forefront: MiR-34a-knockout mice with wild type hematopoietic cells, retain persistent fibrosis following lung injury | |
Asrutdinova et al. | Comparative histological changes in the structure of the spleen and kidneys of experimental chickens exposed to the action of “Guidamis” as an adjuvant for vaccination against infectious bronchitis | |
Reardon | Gene-editing method tackles HIV in first clinical test | |
Ibraimov | The Evolution of Material Basis of Evolution | |
Bricage | CANCER is a Breaking of the Cell's Association for the Reciprocal and Mutual Sharing of Advantages and Disadvantages Through an Aggression that Results in a Lack of Non-Autonomy. | |
Kirthika et al. | Intracellular Survival and Pathogenicity Modulation of Salmonella Lon, CpxR, and RfaL Mutants Used as Live Bacterial Vectors under Abiotic Stress, Unveiling the Link between Stress Response and Virulence in Epithelial Cells | |
CN115837036B (zh) | 黑水虻提取物在制备水产动物寄生虫杀虫剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980136054.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09803076 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010522773 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1203/DELNP/2011 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2009803076 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009803076 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13056443 Country of ref document: US |